Dr. Lu Xianping

EY World Entrepreneur Of The Year^™ 2026 finalist, Chinese mainland
Founder and Chairman, Shenzen Chipscreen Biosciences Co., Ltd.

Dr. Lu Xianping is pioneering new approaches to cancer therapeutics and diabetes management.

Dr. Lu Xianping has emerged as a leading force in global biopharmaceutical innovation, building a career at the intersection of scientific rigor, technological ambition and patient impact. In 2001, he founded Shenzen Chipscreen Biosciences Co., Ltd. with a clear mission: to create first‑in‑class medicines that are not only scientifically groundbreaking but also accessible to patients with urgent, unmet needs. His work has positioned him as one of the early architects of China’s original drug‑discovery ecosystem.

Confronting the high cost and complexity of pharmaceutical research and development, Dr. Lu developed an integrated discovery and early‑evaluation platform using chemical genomics and data‑driven algorithms. This approach shortened development timelines while improving success rates — an achievement that propelled the company to deliver two global first‑in‑class therapies.

The first, chidamide (tucidinostat), is the world’s first subtype‑selective Histone Deacetylase inhibitor and is approved across the Chinese mainland, Macao, Taiwan and Japan for multiple cancers. It is now in late‑stage trials for colorectal cancer and melanoma, while next‑generation epigenetic–immunological ADC therapies advance in parallel. The second, chiglitazar sodium, represents the world’s first pan‑PPAR agonist and a milestone nearly two decades in the making for patients with type 2 diabetes mellitus, particularly those with metabolic syndrome.

Today, Shenzen Chipscreen Biosciences Co., Ltd.’s pipeline spans oncology and metabolic, neurodegenerative and autoimmune diseases, with seven candidates in clinical development and two cleared by the Food and Drug Administration for US trials, reinforcing Dr. Lu’s commitment to delivering transformative therapies worldwide.